

# CITATION REPORT

List of articles citing

## Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status

DOI: 10.1177/2632010X221102054

BMC Clinical Pathology, 2022, 15, 2632010X2211020.

**Source:** <https://exaly.com/paper-pdf/145949528/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Clinical progress of KRAS-targeted therapies: what next?. <i>Future Medicinal Chemistry</i> ,	4.1	0
1	Targeted therapy for lung cancer: Beyond EGFR and ALK.		0